Abdul Mohiuddin, MD
Family Medicine · Hopewell, VANPI 1003885575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,168 and has fallen 57.7% since, to $494 in 2025.
Across 201 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$776
- Amgen$586
- Novartis$481
- Supernus Pharmaceuticals, Inc.$390
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$241
- GSK$230
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,67698%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $776 |
| Amgen | 21 | $586 |
| Novartis | 22 | $481 |
| Supernus Pharmaceuticals, Inc. | 16 | $390 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $241 |
| GSK | 11 | $230 |
| E.r. Squibb & Sons, L.L.C. | 2 | $215 |
| Otsuka America Pharmaceutical, Inc. | 3 | $157 |
| Sunovion Pharmaceuticals Inc. | 14 | $154 |
| Seagen Inc. | 1 | $125 |
| Pfizer | 7 | $125 |
| Valeritas, Inc. | 8 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $119 |
| Astellas Pharma US Inc | 4 | $116 |
| UCB, Inc. | 6 | $109 |
| Radius Health, Inc. | 1 | $106 |
| Bayer | 3 | $105 |
| Dexcom, Inc. | 4 | $77 |
| Lilly USA, LLC | 5 | $74 |
| AbbVie | 3 | $56 |
| Johnson & Johnson | 4 | $53 |
| Viatris Specialty LLC | 2 | $43 |
| Amarin Pharma, Inc. | 3 | $41 |
| Novo Nordisk | 2 | $31 |
| Penumbra, Inc. | 1 | $31 |
| Medtronic(2 entities) | 2 | $29 |
| Neurocrine Biosciences, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Abbott | 1 | $12 |
| Merck | 1 | $12 |
| Insulet Corporation | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,751 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 592 | $215,598 |
| TrulicityDulaglutide | 139 | $127,672 |
| AustedoDeutetrabenazine | 55 | $110,811 |
| NuplazidPimavanserin Tartrate | 45 | $102,324 |
| JardianceEmpagliflozin | 199 | $76,097 |
| IngrezzaValbenazine Tosylate | 15 | $54,308 |
| NuedextaDextromethorphan Hbr/Quinidine | 55 | $46,289 |
| LinzessLinaclotide | 74 | $43,460 |
| JanuviaSitagliptin Phosphate | 110 | $42,345 |
| OzempicSemaglutide | 36 | $39,445 |
| XareltoRivaroxaban | 92 | $37,562 |
| EntrestoSacubitril/Valsartan | 79 | $32,286 |
| FarxigaDapagliflozin Propanediol | 88 | $29,762 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $28,171 |
| MyrbetriqMirabegron | 88 | $25,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $125 | $215,598592 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $74 | $139,177150 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $776 | $83,199226 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $27 | $54,30815 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $13 | $46,28955 claims |
| AbbVieLinzess | $56 | $43,46074 claims |
| MerckJanuvia | $12 | $42,345110 claims |
| Novo NordiskOzempic | $31 | $39,44536 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Arexvy, Breo Ellipta | $230 | $37,76883 claims |
| Johnson & JohnsonXarelto | $53 | $37,56292 claims |
| NovartisEntresto | $481 | $32,28679 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $25,97288 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Hopewell
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.